Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.72 EUR
Change Today -0.086 / -4.78%
Volume 12.2K
VIU On Other Exchanges
As of 1:37 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

vivus inc (VIU) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - €2.87
52 Week Low
08/25/15 - €0.81
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIVUS INC (VIU)

vivus inc (VIU) Related Businessweek News

View More BusinessWeek News

vivus inc (VIU) Details

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

94 Employees
Last Reported Date: 02/25/15
Founded in 1991

vivus inc (VIU) Top Compensated Officers

Chief Executive Officer, Chief Commercial Off...
Total Annual Compensation: $650.0K
Senior Vice President of Business Development...
Total Annual Compensation: $425.0K
Vice President of Clinical Development
Total Annual Compensation: $432.3K
Vice President of Medical & Regulatory Affair...
Total Annual Compensation: $385.0K
Compensation as of Fiscal Year 2014.

vivus inc (VIU) Key Developments

VIVUS Inc. Announces Management Changes

On September 30, 2015, the Board of Directors of VIVUS Inc. appointed Johann Noor Mohamed, the company's Vice President and Corporate Controller, to serve as the company's interim Chief Financial Officer and interim Chief Accounting Officer, effective October 1, 2015. Mr. Noor Mohamed served as the company's Vice President and Corporate Controller from June 2015 to September 2015, as the company's Corporate Controller from January 2014 to May 2015 and as the company's Assistant Controller from October 2012 to December 2013. In addition, on September 30, 2015, the Board of Directors of the company appointed Mark K. Oki to serve as the company's Chief Financial Officer and Chief Accounting Officer effective October 19, 2015. Mr. Noor Mohamed has agreed to resign from the position of interim Chief Financial Officer and interim Chief Accounting Officer and resume his service as the company's Vice President and Corporate Controller, as of the effective date of Mr. Oki's appointment as the company's Chief Financial Officer and Chief Accounting Officer.

VIVUS Inc. Amend and Restate its Bylaws

In connection with Messrs. Roberts, Shaw and Sriskandarajah’s appointment as directors, the Board amended VIVUS Inc. amended and restated bylaws to state that the number of directors that shall constitute the Board will be determined from time to time by resolution of the Board, but in no event shall the number be less than three.

VIVUS Inc. Announces Executive Appointments

On September 15, 2015, the Board of Directors of VIVUS Inc. appointed Eric W. Roberts, Allan L. Shaw and Mayuran Sriskandarajah as directors of the company. The Board has determined that Messrs. Roberts, Shaw and Sriskandarajah are independent of the company and its management as defined by the Securities and Exchange Commission and the NASDAQ Listing Rules. There were not any arrangements or understandings between Messrs. Roberts, Shaw or Sriskandarajah and any other persons pursuant to which they were elected as directors. Since January 2012, Mr. Roberts has been a founding Managing Director of Valence Life Sciences, LLC. From 2004 to 2012, Mr. Roberts was a founding Managing Director of Caxton Advantage Venture Partners. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as Managing Director, Partner and Founder of the Life Sciences Department at Dillon, Read & Co. Inc. and Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers. Mr. Roberts currently serves on the board of directors of Invuity Inc. and Chinook Pharmaceuticals. He also served on the board of directors of Gemin X Pharmaceuticals Inc. Mr. Shaw was Managing Director of Alvarez & Marsal LLC and led their biopharmaceutical consulting practice, from December 2011 to March 2015, and continues to support the firm on an adhoc basis. From 2009 to 2011, he served as the Chief Financial Officer of NewLead Holdings LTD. From 2005 to 2009, he was the founder and Senior Managing Director of Shaw Strategic Capital LLC focused on providing strategic financial counsel on a wide variety of issues such as general corporate finance, mergers and acquisitions, capital structuring, licensing and capital markets. From 2002 to 2004, Mr. Shaw was the Chief Financial Officer of Serono S.A. and from 1994 to 2001, he was the Chief Financial Officer of Viatel Inc. Mr. Shaw serves on the board of directors of Akari Therapeutics, Plc. and Edith & Carl Marks JCH of Bensonhurst. He also served on the board of directors of the Central New York Biotech Accelerator from 2009 to 2013, NewLead Holdings LTD. from 2009 to 2011, Navios Maritime Holdings Inc. from 2005 to 2010, Serono S.A. as an Executive Management Board Member from 2002 to 2004 and Viatel Inc. from 1996 to 2002. He has contributed to several corporate governance books and is a member of the American Institute of Certified Public Accountants, New York Society of Certified Public Accountants and Corporate Directors Group. Mr. Sriskandarajah is a founding partner and Managing Director of Sarissa Capital Management LP. From 2005 to 2010, Mr. Sriskandarajah served as an Investment Analyst at Icahn Capital, an entity through which Carl C. Icahn conducts his investment activities, and in 2011, he served as a consultant at Icahn Capital. Prior to Icahn Capital, he served as a consultant at Bain & Company, from 2002 to 2005. Prior to this, Mr. Sriskandarajah served as an investment banker at Wasserstein Perella & Company. Mr. Sriskandarajah has served on the board of directors of Emmaus Life Sciences Inc. He also served on the board of directors of Viskase Companies Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIU:GR €1.72 EUR -0.086

VIU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $2.19 USD +0.14
GlaxoSmithKline Consumer Healthcare Ltd 6,051 INR +13.00
Novo Nordisk A/S kr357.10 DKK -1.20
Orexigen Therapeutics Inc $2.53 USD +0.15
Takeda Pharmaceutical Co Ltd ¥5,505 JPY +82.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VIU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at